Study to Assess Safety, Tolerability and Pharmacokinetics after Single Doses of AZD2516 to Healthy Volunteers
Study identifier:D2080C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single-centre, Randomised, Double-blind, Placebo-controlled Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2516 in Young and Elderly Healthy Volunteers after Oral Single Ascending Doses
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD2516, Placebo
Sex
All
Actual Enrollment
72
Study type
Interventional
Age
20 Years - 80 Years
Date
Study Start Date: 01 Sept 2008
Primary Completion Date: 01 Nov 2008
Study Completion Date: 01 Dec 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD2516 | Drug: AZD2516 Solution administered once orally |
| Placebo Comparator: Placebo | Drug: Placebo Solution administered only once |
Contacts
Investigators
Principal Investigator
Bo Fransson
AstraZeneca
